Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.

ABSTRACT:

Background

Despite major advancements in immunotherapy among a number of solid tumors, response rates among ovarian cancer patients remain modest. Standard treatment for ovarian cancer is still surgery followed by taxane- and platinum-based chemotherapy. Thus, there is an urgent need to develop novel treatment options for clinical translation.

Methods

Our approach was to analyze the effects of standard chemotherapy in the tumor microenvironment of mice harboring orthotopic, syngeneic ID8-Vegf-Defb29 ovarian tumors in order to mechanistically determine a complementary immunotherapy combination. Specifically, we interrogated the molecular and cellular consequences of chemotherapy by analyzing gene expression and flow cytometry data.

Results

These data show that there is

SUBMITTER: Hartl CA 

PROVIDER: S-EPMC6668091 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature